Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2604-2610

  Cheradame S ^a   Etienne, M C ^a   Formento, P ^a   Schneider, M ^a   Dassonville, O ^a   Demard, F ^a   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; METHYLENETETRAHYDROFOLIC ACID; TETRAHYDROFOLIC ACID; THYMIDYLATE SYNTHASE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFICACY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0342941149     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2604     Document Type: Article

References (36)

1. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
2. Lefevre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organisation for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 88:890-899, 1996
3. Vokes EE, Schilsky RC, Weichselbaum RR, et al: Induction chemotherapy with cisplatin, fluorouracil and high dose leucovorin for locally advanced head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 8:241-247, 1990
4. Danenberg PV, Danenberg KD: Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthase: Evidence for an ordered mechanism. Biochemistry 17:4018-4024, 1978
5. Rustum YM, Trave F, Zakrzewski SF, et al: Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 5:165-170, 1987
6. Keyomarsi K, Moran RG: Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 263:14402-14409, 1988
7. Houghton JA, Maroda SJ Jr, Phillips JO, et al: Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adeno-carcinomas in mice. Cancer Res 41:144-149, 1981
8. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
9. Poon MA, O'Connel MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
10. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990
11. Piedbois P, Buyse M, Rustum Y, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
12. Jäger E, Heike M, Bernhard H, et al: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial. J Clin Oncol 14:2274-2279, 1996
13. Cao S, Frank C, Rustum YM: Role of fluoropyrimidine schedule and (6 R, S) leucovorin dose in a preclinical animal model of colorectal carcinoma. J Natl Cancer Inst 88:430-436, 1996
14. Laccourreye O, Brasnu D, Bassot V, et al: Cisplatin-fluorouracil exclusive chemotherapy for T1-T3 NO glottic squamous cell carcinoma complete clinical responders: Five-year results. J Clin Oncol 14:2331-2336, 1996
15. Etienne MC, Chéradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995
16. Beck A, Etienne MC, Chéradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30:1517-1522, 1994
17. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412, 1995
18. Lenz HJ, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182, 1995
19. Moran RG, Spears CP, Heidelberger C: Biochemical determination of tumor sensitivity to 5-fluoro-2′deoxyuridilate 2′deoxyuridine and thymidylate synthase. Proc Natl Acad Sci USA 76:1456-1460, 1979
20. 4Pteglu assays, in Rustum Y, McGuire JJ (eds): The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. New York, NY, Plenum, 1988, pp 97-104
21. Bunni M, Doig MT, Donato H, et al: Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells. Cancer Res 48:3398-3404, 1988
22. Thyss A, Schneider M, Santini J, et al: Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer 54:755-760, 1986
23. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck. N Engl J Med 328:184-194, 1993
24. Peters GJ, Van Groeningen CJ, Van derWilt C, et al: Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Semin Oncol 19:26-35, 1992
25. Trave F, Rustum YM, Petrelli NJ, et al: Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol 6:1184-1191, 1988
26. Halsted CH: Folate deficiency in alcoholism. Am J Clin Nutr 33:2736-2740, 1980
27. Gates SB, Mendelsohn LG, Shackelford KA, et al: Characterization of folate receptor from normal and neoplastic murine tissue: Influence of dietary folate on folate receptor expression. Clin Cancer Res 2:1135-1141, 1996
28. Sotos GA, Allegra CJ: Biochemical modulation of cancer chemotherapy, in Schilsky RL, Milano G, Ratain MJ (eds): Principles of Antineoplastic Drug Development and Pharmacology. New York, NY, Marcel Dekker, 1996, pp 189-202
29. Vokes EE, Schilsky RL, Weichselbaum RR, et al: Induction chemotherapy with cisplatin, fluorouracil and high-dose leucovorin for locally advanced head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 8:241-247, 1990
30. Schneider M, Etienne MC, Milano G, et al: Phase II trial of cisplatin, fluorouracil and pure 1 folinic acid for locally advanced head and neck cancer: A pharmacokinetic and clinical survey. J Clin Oncol 13:1656-1662, 1995
31. Doroshow JH: Biochemical modulation of fluoropyrimidines: Is there an optimal (6R, S) leucovorin dose and schedule? J Natl Cancer Inst 88:393-395, 1996
32. Dimery JW, Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 86:95-111, 1993
33. Scanlon KJ, Newman EM, Lu Y, et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923-8925, 1986
34. Shirasaka T, Shimamoto Y, Cheshimo H, et al: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32:167-172, 1993
35. Antony AC: The biological chemistry of folate receptors. Blood 79:2807-2820, 1992
36. Boarman DM, Allegra CJ: Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res 52:36-44, 1992